Kesimpta (Ofatumumab) for Multiple Sclerosis

Overview
Kesimpta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsing forms of multiple sclerosis in adults. Kesimpta is also referred to by its drug name, ofatumumab.

Kesimpta is a biologic immunomodulator, a drug that changes the immune system. Kesimpta is a CD20-directed cytolytic antibody (a protein used by the immune system to identify and neutralize substances). Kesimpta is believed to work by reducing the number of CD20-positive B cells, a type of immune system cell involved in relapsing multiple sclerosis.

How do I take it?
Kesimpta is administered by injection under the skin. Kesimpta comes as a single-use, prefilled pen or syringe.

Consult your doctor before receiving vaccines while taking Kesimpta.

Side effects
The FDA-approved label for Kesimpta lists common side effects including headache, irritation at the injection site, injection-related reactions, and upper respiratory tract infection.

Rare but serious side effects listed for Kesimpta include opportunistic infections and fetal harm.

For more details about this treatment, visit:
Kesimpta — Novartis